A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC. (2022)
Attributed to:
Driving innovation in precision medicine through translational life sciences research at the University of Leicester
funded by
UKRI
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/cancers14030779
PubMed Identifier: 35159046
Publication URI: http://europepmc.org/abstract/MED/35159046
Type: Journal Article/Review
Volume: 14
Parent Publication: Cancers
Issue: 3
ISSN: 2072-6694